CN106170296A - 具有能被广谱中和抗体识别的抗原表位的hiv‑1包膜蛋白及其片段 - Google Patents

具有能被广谱中和抗体识别的抗原表位的hiv‑1包膜蛋白及其片段 Download PDF

Info

Publication number
CN106170296A
CN106170296A CN201380057199.5A CN201380057199A CN106170296A CN 106170296 A CN106170296 A CN 106170296A CN 201380057199 A CN201380057199 A CN 201380057199A CN 106170296 A CN106170296 A CN 106170296A
Authority
CN
China
Prior art keywords
fragment
hiv
binding
envelope protein
glycosylation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380057199.5A
Other languages
English (en)
Chinese (zh)
Inventor
P·W·伯曼
G·辰乃
俞彬
J·莫拉莱斯
K·梅萨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CN106170296A publication Critical patent/CN106170296A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201380057199.5A 2012-09-11 2013-09-11 具有能被广谱中和抗体识别的抗原表位的hiv‑1包膜蛋白及其片段 Pending CN106170296A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261699680P 2012-09-11 2012-09-11
US61/699,680 2012-09-11
PCT/US2013/059243 WO2014043220A2 (en) 2012-09-11 2013-09-11 Hiv-1 envelope proteins and fragments thereof that possess epitopes recognized by broadly neutralizing antibodies

Publications (1)

Publication Number Publication Date
CN106170296A true CN106170296A (zh) 2016-11-30

Family

ID=50278843

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380057199.5A Pending CN106170296A (zh) 2012-09-11 2013-09-11 具有能被广谱中和抗体识别的抗原表位的hiv‑1包膜蛋白及其片段

Country Status (7)

Country Link
US (2) US9731002B2 (enExample)
EP (1) EP2928492A4 (enExample)
CN (1) CN106170296A (enExample)
AU (1) AU2013315631B2 (enExample)
CA (1) CA2929937C (enExample)
IN (1) IN2015DN03026A (enExample)
WO (1) WO2014043220A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106800603A (zh) * 2017-01-24 2017-06-06 中国食品药品检定研究院 检测抗hiv抗体的adcc活性的方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2739300B1 (en) 2011-07-05 2019-06-19 Duke University N-terminal deleted gp120 immunogens
CA2850745C (en) 2011-10-03 2022-12-13 Duke University Vaccine
US10517942B2 (en) 2015-08-01 2019-12-31 The Regents Of The University Of California Polypeptide glycopeptide fragments from the V1/V2 and V3 domains of the HIV-1 envelope protein gp 120
US20200231633A1 (en) * 2017-07-19 2020-07-23 The Regents Of The University Of California MGAT1-Deficient Cells for Production of Vaccines and Biopharmaceutical Products
US20210317168A1 (en) * 2018-10-15 2021-10-14 The Regents Of The University Of California Complement Component 1s (C1s) Deficient Cells for Production of Vaccines and Biopharmaceutical Proteins
US20250059238A1 (en) * 2018-12-03 2025-02-20 International Aids Vaccine Initiative Recombinant hiv env polypeptides and their uses

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102803292A (zh) * 2009-04-20 2012-11-28 辉瑞公司 蛋白质糖基化的控制及其相关组合物和方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2345959A1 (en) * 1998-09-29 2000-04-06 University Of Kansas Medical Center Live virus vaccines to protect primates from hiv-1 infection and disease
WO2005097822A1 (en) * 2004-04-09 2005-10-20 University Of Manitoba Identification of the precise amino acid sequence of the epitope recognized by the potent neutralizing human anti-hiv-1 monoclonal antibody igg1b12
US9782472B2 (en) 2008-10-04 2017-10-10 The Regents Of The University Of California Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity
CA2768149A1 (en) * 2009-07-14 2011-01-20 Lucia Irene Gonzalez Stereoisomer peptides and their polymer conjugates for hiv disease
EP2588211A4 (en) * 2010-06-30 2014-03-05 Torrey Pines Inst EPS TRIMER-IMMUNOGENIC
WO2013085550A2 (en) 2011-12-05 2013-06-13 Duke University V1v2 immunogens

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102803292A (zh) * 2009-04-20 2012-11-28 辉瑞公司 蛋白质糖基化的控制及其相关组合物和方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
UNIPROTKB: "C9W4T0 (C9W4T0_9HIV1)", 《UNIPROTKB》 *
YU BIN,等: "Glycoform and Net Charge Heterogeneity in gp120 Immunogens Used in HIV Vaccine Trials", 《PLOS ONE》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106800603A (zh) * 2017-01-24 2017-06-06 中国食品药品检定研究院 检测抗hiv抗体的adcc活性的方法
CN106800603B (zh) * 2017-01-24 2020-07-28 中国食品药品检定研究院 检测抗hiv抗体的adcc活性的方法

Also Published As

Publication number Publication date
WO2014043220A2 (en) 2014-03-20
US20180036401A1 (en) 2018-02-08
IN2015DN03026A (enExample) 2015-10-02
CA2929937A1 (en) 2014-03-20
EP2928492A4 (en) 2017-09-13
WO2014043220A3 (en) 2016-10-27
EP2928492A2 (en) 2015-10-14
AU2013315631B2 (en) 2018-04-19
US9731002B2 (en) 2017-08-15
CA2929937C (en) 2020-01-07
AU2013315631A1 (en) 2015-04-30
US10507239B2 (en) 2019-12-17
US20150246111A1 (en) 2015-09-03

Similar Documents

Publication Publication Date Title
US10507239B2 (en) V1/V2 fragments of a HIV-1 envelope glycoprotein
Hovanessian et al. The caveolin-1 binding domain of HIV-1 glycoprotein gp41 is an efficient B cell epitope vaccine candidate against virus infection
EP4001304A1 (en) Broadly neutralizing antibody and uses thereof
JP2003529319A (ja) ＨＩＶ−１ｇｐ４１を標的化する広範に中和する抗体を誘発する方法
US20170035877A1 (en) Soluble hiv-1 envelope glycoprotein trimers
WO2011109511A2 (en) Novel hiv-1 envelope glycoprotein
Ximba et al. Development of a synthetic nanoparticle vaccine presenting the HIV-1 envelope glycoprotein
Moseri et al. An optimally constrained V3 peptide is a better immunogen than its linear homolog or HIV-1 gp120
US20150313990A1 (en) Hiv therapeutics and methods of making and using same
Joachim et al. Induction of identical IgG HIV-1 envelope epitope recognition patterns after initial HIVIS-DNA/MVA-CMDR immunization and a late MVA-CMDR boost
CN110248954B (zh) 在植物中产生可溶性hiv包膜三聚体
P. Carter et al. Peptide triazole inhibitors of HIV-1: hijackers of env metastability
Gao et al. Centralized HIV-1 envelope immunogens and neutralizing antibodies
AU2020367242A1 (en) Influenza virus vaccines and uses thereof
Leaman et al. Membrane Env liposomes facilitate immunization with multivalent full-length HIV spikes
JP4714213B2 (ja) 新規ｔａｔ複合体及びそれらを含むワクチン
US8475799B2 (en) HIV-1 GP41 neutralization domain and use thereof
CA3211186A1 (en) Hiv-1 envelope glycopeptide nanoparticles and their uses
Mayr et al. Antibodies targeting the envelope of HIV‐1
WO2017023857A1 (en) Polypeptide glycopeptide fragments from the v1/v2 and v3 domains of the hiv-1 envelope protein gp 120
CN119552226B (zh) 一种拉沙病毒gpc蛋白融合前构象突变体及应用
JP2013528370A (ja) Ｈｉｖ−１サブタイプｃエンベロープ糖タンパク質における遺伝子シグネチャー
CA2509387A1 (en) Peptide oligomers for use as hiv vaccines
Khan et al. Informatics in Medicine Unlocked
EP3104884B1 (en) A new non-hiv vaccine antigen from the vaginal microbiota capable of inducing a mucosal neutralizing protective antibody response against hiv infection

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20161130

RJ01 Rejection of invention patent application after publication